XELLIA PHARMACEUTICALS ApS: Financial statements 2018
CVR: 61094628
Source: annual report 2018, Danish Business Authority
01/01/2018 – 31/12/2018
XELLIA PHARMACEUTICALS ApS (CVR 61094628) has filed annual accounts for 2018. In 2018, the company reported revenue of DKK 1,890,464,000 and a net result of DKK -74,912,000 compared with DKK 91,002,000 the year before. That is a decrease of 0.3% compared with the year before. The profit margin was -4%. Equity in the 2018 report amounted to DKK 1,007,124,000. The solvency ratio was 41.5%. The company had 580 employees in the financial year.
- Revenue
- DKK 1,890,464,000
- Gross Profit
- DKK 576,673,000
- Profit/Loss
- DKK -74,912,000
- Equity
- DKK 1,007,124,000
- Total Assets
- DKK 2,426,495,000
- Employees
- 580
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2018 | 1.9B | 576.7M | -74.9M | 1B | 580 |
| 2017 | 1.9B | 528.3M | 91M | 850.8M | 493 |
| 2016 | 1.5B | 521.8M | 33.8M | 758.8M | 466 |
| 2015 | 1.2B | 364.2M | -74M | 729.2M | 479 |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record, straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2018
XELLIA PHARMACEUTICALS ApS has published its annual report for 2017. Revenue came to DKK 1,897,063,000, and the net result was DKK 91,002,000.
As of March 22, 2018, Lone Thiis has joined the board of directors of XELLIA PHARMACEUTICALS ApS.
As of March 22, 2018, Lars Beck Madsen has joined the board of directors of XELLIA PHARMACEUTICALS ApS.
As of March 22, 2018, Thomas Schou Hunderup has joined the board of directors of XELLIA PHARMACEUTICALS ApS.
As of March 22, 2018, Jakob Christian Andersen has joined the board of directors of XELLIA PHARMACEUTICALS ApS.
As of March 22, 2018, Lennart Bo Fredmark has left the board of directors of XELLIA PHARMACEUTICALS ApS.
As of March 22, 2018, Lars Mosberg has left the board of directors of XELLIA PHARMACEUTICALS ApS.
As of March 22, 2018, Lone Finner has left the board of directors of XELLIA PHARMACEUTICALS ApS.
As of March 21, 2018, Thomas Schou Hunderup has left the board of directors of XELLIA PHARMACEUTICALS ApS.
As of January 3, 2018, Niels Murmann has joined the board of directors of XELLIA PHARMACEUTICALS ApS.
About XELLIA PHARMACEUTICALS ApS
XELLIA PHARMACEUTICALS ApS is a Danish company of the type Anpartsselskab based in København S, founded in 1959. The company is registered under the industry Fremstilling af farmaceutiske råvarer. The company was previously named AXELLIA PHARMACEUTICALS ApS and ALPHARMA ApS. The management consists of Michael Kocher. The board consists of Søren Hostrup (chair), Alexander Sebastian Benjamin Sproedt, Hugo Mendes Marques Crespo Dos Reis and Lars Beck Madsen. The company is owned by XELLIA GROUP ApS. The company has 461 employees (2026). In 2025, the company reported revenue of DKK 1,461,516,000 and a net result of DKK 213,738,000 compared with DKK 828,966,000 the year before. Equity in the 2025 report amounted to DKK 404,569,000.